• Sofinnova Partners portfolio company Rezera reported Phase 1 topline results for oral NLRP3 inhibitor trabzanoflast.
• Trial showed no serious adverse events, no discontinuations, no clinically significant safety lab changes across single and multiple ascending doses.
• Continuous cerebrospinal fluid sampling indicated high CNS exposure, with Kp,uu of 1.9.
• Pharmacokinetics were dose-proportional; pharmacodynamics showed target engagement in CSF, supporting continued clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sofinnova Partners SAS published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.